CAH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cardinal Health is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 who is impatient and wants an immediate decision. The stock looks technically strong and has supportive analyst coverage, but it is also overbought after a sharp run, so the current price is not the best entry. My direct view: hold and wait for a better pullback rather than buying today.
CAH is in a bullish trend: SMA_5 is above SMA_20 and SMA_20 is above SMA_200, and the MACD histogram is positive and expanding, which confirms upward momentum. However, RSI_6 is 89.52, which is extremely overbought and suggests the stock has likely moved too far too fast in the near term. Price at 221.25 is just above the R1 level of 218.858 and below R2 at 225.908, so it is trading near short-term resistance rather than a clean entry zone. Overall trend is bullish, but the immediate setup is stretched.
Healthcare is attracting rotation as investors move away from tech and into defensive sectors. Analyst coverage remains generally positive, with multiple Buy/Outperform ratings maintained. TD Cowen, Baird, Citi, BofA, William Blair, and Evercore all remain constructive overall, and several firms raised or maintained favorable targets after quarterly results. The company also had supportive commentary from BofA noting stronger Pharma/Other segment performance and raised FY26 EPS guidance.
JPMorgan lowered its price target to $215 and kept a Neutral rating, showing some valuation caution. The stock is extended technically with an overbought RSI, which makes the current price less attractive for fresh long-term capital. The mixed analyst target revisions indicate that while sentiment is still positive overall, expectations are becoming more measured after the recent run-up.
No detailed latest-quarter income statement or balance sheet figures were provided, so a full financial assessment is limited. Based on the available analyst commentary, the latest quarter appears to have been mixed-to-positive, with Cardinal Health raising FY26 EPS guidance and showing continued strength in the Pharma/Other segments. This suggests improving earnings momentum in the most recent quarter season, even though exact revenue and profit growth numbers are unavailable here.
The analyst trend is still constructive, but targets have generally been nudged down slightly rather than sharply raised. Recent calls include Buy/Outperform ratings from TD Cowen, Baird, Citi, BofA, William Blair, and Evercore, while JPMorgan is Neutral. The range of targets is still mostly above the current price, but the average target movement has softened, suggesting Wall Street sees upside, though not enough to justify aggressive buying at current levels. Overall pros: durable distribution moat, favorable healthcare rotation, and solid earnings guidance. Cons: some valuation compression, mixed target cuts, and less room for immediate upside after the recent rally.
